-
PRAC highlights May 2021
PRAC highlights May 2021
-
PRAC highlights May 2021
PRAC highlights May 2021
Outcomes from the May meeting cover all aspects of the risk management of the use of medicines, including COVID-19 vaccines
-
Rolling review of VIR-7831 antibody for COVID-19 started
Rolling review of VIR-7831 antibody for COVID-19 started
-
Rolling review of VIR-7831 antibody for COVID-19 started
Rolling review of VIR-7831 antibody for COVID-19 started
EMA is starting a ‘rolling review’ of data on VIR-7831, a monoclonal antibody for the treatment of COVID-19 developed by GlaxoSmithKline and Vir Biotechnology
-
Becoming a member of a scientific advisory group
Becoming a member of a scientific advisory group
-
Becoming a member of a scientific advisory group
Becoming a member of a scientific advisory group
EMA is calling for European clinical / technical experts to express their interest in becoming members of the Scientific Advisory Groups. Deadline June 4 2021
-
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
-
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
Start of rolling review: COVID-19 Vaccine (Vero Cell) Inactivated
The decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies
